<a href="https://laohu8.com/S/LIXT">Lixte Biotechnology Holdings Inc.</a> Announces Breakthrough Clinical Trial for LB-100, the World's Only Clinical-Stage PP2A Inhibitor, Targeting <a href="https://laohu8.com/S/CTHZ">Cancer Treatment</a> Synergies
Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT) has announced the continuation of its clinical programs involving LB-100, a first-in-class protein phosphatase 2A (PP2A) inhibitor, designed to enhance cancer treatment. LB-100 is currently being evaluated in collaboration with pharmaceutical partners in various cancer studies. These include a trial for ovarian clear-cell carcinoma in partnership with GSK, which is providing Dostarlimab and supporting full trial funding. Additionally, LB-100 is being assessed for MSS colorectal cancer in collaboration with Roche at the Netherlands Cancer Institute, although this study is currently under a temporary voluntary safety pause due to early adverse events. The results of these trials have not yet been presented, as the studies are ongoing. Lixte aims to validate LB-100's safety and efficacy and explore its potential to improve the effectiveness of existing cancer therapies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lixte Biotechnology Holdings Inc. published the original content used to generate this news brief via Newsfile (Ref. ID: 265118) on September 05, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。